ClinicalTrials.gg
RecruitingNCT07600333CHOSAUpdated Nov 19, 2026

CPAP vs High-Flow Nasal Cannula for Treating Sleep Apnea in Children

An interventional study of High Flow Nasal Cannula and Continuous Positive Airway Pressure in Obstructive Sleep Apnea (OSA), sponsored by The Hospital for Sick Children. Recruiting at 1 site in Canada. Open to participants aged 2 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by The Hospital for Sick Children · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2026; still recruiting 5 months later.
Updated Nov 19, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
258
Allocation
Randomized
Ages
2 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 133 studies in Sleep Apnea, Obstructive with a site in Canada — 22 open to participants now, 31 under way, 4 of them phase 3. Sleep Apnea, Obstructive · Canada.

Planned enrollment
15th of 102
258 · median 60
Started
2026
with 1 other
No phase
70 of 133
9 open now
Primary completion
2031-11
later than 30 of 30 live
Registered
132nd of 133
by date
Lead sponsor
9 of 133
The Hospital for Sick Children

Among the 133 studies in Sleep Apnea, Obstructive with a site in Canada, this one is the 15th largest by planned enrollment of the 102 interventional ones that give a count, is one of 2 that started in 2026, is one of 70 with no phase, reaches primary completion later than 30 of the 30 other live ones, and was the 132nd registered.

Sleep Apnea, Obstructive

2,246 studies on the registry are indexed under Sleep Apnea, Obstructive; 476 are open to participants now.

Browse Sleep Apnea, Obstructive studies →

Open to participants now

22 of the 133 studies in Sleep Apnea, Obstructive with a site in Canada are open now. Recruiting first, the newest first:

16 more — sign in →

All 22 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 317 Sleep Apnea, Obstructive studies recruiting now, 149 (47%) set no upper age limit and 124 (39%) stop at 75 or younger; 53 take children under 18; 66 take healthy volunteers.

This study: 2 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 133 studies in Sleep Apnea, Obstructive with a site in Canada, or all of them as a file.
02

Study summary

This study is looking at two different treatments for obstructive sleep apnea (OSA) in children. OSA is a sleep condition where breathing repeatedly stops and starts during sleep, which can affect a child's health, behavior, learning, and quality of life.

Children with moderate-to-severe OSA who cannot be treated with surgery are often prescribed Continuous Positive Airway Pressure (CPAP). CPAP uses a mask worn during sleep to deliver pressurized air and keep the airway open. Although CPAP is effective, many children have difficulty using it regularly because it can feel uncomfortable or hard to tolerate.

This study compares CPAP with another treatment called High-Flow Nasal Cannula (HFNC). HFNC delivers warm, humidified air through soft nasal prongs and may be more comfortable and easier for children to use while still helping keep the airway open during sleep.

Children aged 2 to 18 years with moderate-to-severe OSA will be randomly assigned to use either CPAP or HFNC at home during sleep for 3 months. The study will measure how much each treatment is used, how well it improves sleep-related symptoms and quality of life, how comfortable it is for children, and how it affects caregivers.

The goal of this study is to find out whether HFNC is a comfortable and effective alternative to CPAP for treating obstructive sleep apnea in children.

Read the detailed description

Obstructive sleep apnea (OSA) is a common pediatric condition characterized by repeated episodes of upper airway obstruction during sleep. These episodes disrupt normal sleep patterns and oxygenation and are associated with significant short- and long-term health consequences. In children, untreated moderate-to-severe OSA has been linked to impaired quality of life, behavioral and emotional difficulties, impaired learning and school performance, cardiovascular and metabolic effects, and increased caregiver stress and health care utilization.

For many children, adenotonsillectomy is the first-line treatment; however, a substantial proportion continue to experience residual OSA after surgery or are not suitable surgical candidates. In these cases, Continuous Positive Airway Pressure (CPAP) therapy is the standard treatment. CPAP delivers pressurized air through a mask worn during sleep to keep the airway open. While CPAP is effective under optimal conditions, real-world effectiveness in pediatric populations is limited by low tolerance and adherence. Common challenges include discomfort related to the mask interface, claustrophobia, air pressure intolerance, and family burden associated with nightly device use.

High-Flow Nasal Cannula (HFNC) therapy has emerged as a potential alternative for treating pediatric OSA. HFNC delivers warmed, humidified air at high flow rates through soft nasal prongs and can generate positive airway pressure that supports upper airway patency. Compared with CPAP, HFNC may be perceived as less intrusive and more comfortable, which could improve adherence and overall treatment effectiveness. Preliminary physiologic studies and small clinical trials suggest that HFNC can reduce OSA severity; however, there is limited evidence comparing HFNC and CPAP in children, particularly over extended periods of use in home settings.

The CHOSA Trial was designed to address this evidence gap by directly comparing CPAP and HFNC in children with moderate-to-severe OSA who require non-surgical therapy. The study evaluates the real-world use of these therapies in the home environment, with a focus on treatment adherence as well as patient- and family-centered outcomes. By embedding the intervention within routine clinical care across multiple centers, the study aims to reflect typical pediatric sleep medicine practice and enhance the generalizability of its findings.

Participants receive comprehensive education and support to promote safe and effective use of their assigned therapy. Device setup, fitting, and optimization are performed by trained respiratory therapists, and treatment is titrated using standard sleep study procedures to ensure appropriate therapeutic settings. During the home treatment period, participants and caregivers receive ongoing clinical support consistent with usual care, including troubleshooting for comfort and usability concerns.

The primary focus of the study is adherence to therapy, assessed using objective device data. Secondary aspects of the study evaluate the broader impact of treatment on sleep-related symptoms, quality of life, comfort, psychosocial functioning, caregiver burden, and health economic outcomes using validated instruments. These outcomes were selected to capture not only physiological effectiveness, but also the acceptability and practicality of each treatment from the perspective of children and families.

A qualitative component is incorporated to provide a deeper understanding of participant and caregiver experiences. Through semi-structured interviews, the study explores perceived benefits and challenges of CPAP and HFNC, factors influencing nightly use, strategies families employ to support adherence, and the impact of therapy on daily routines and well-being. This qualitative information complements quantitative findings and helps contextualize adherence and outcome data.

Both CPAP and HFNC are commonly used non-invasive respiratory therapies with established safety profiles in pediatric care. Safety monitoring is conducted throughout the study, and adverse events are documented in accordance with ethical and regulatory requirements. Participation is voluntary, and families may withdraw at any time without affecting the child's clinical care.

By comparing CPAP and HFNC in a large, diverse pediatric population using real-world home use conditions, the CHOSA Trial aims to inform clinical decision-making and guideline development. The results are expected to clarify whether HFNC offers a more acceptable or effective alternative for children who struggle with standard CPAP therapy and to support evidence-based expansion of treatment options for pediatric obstructive sleep apnea.

03

Conditions studied

  • Obstructive Sleep Apnea (OSA)

Keywords

  • obstructive sleep apnea
  • pediatric obstructive sleep apnea
  • children
  • adolescents
  • continuous positive airway pressure
  • CPAP
  • High Flow nasal cannula
  • HFNC
  • Sleep-disordered breathing
  • adherence
  • quality of life
  • home sleep therapy
  • randomized controlled trial
04

Who can participate

Ages eligible
2 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 2 to 18 years
  • Diagnosed with moderate to severe obstructive sleep apnea, defined as an obstructive apnea-hypopnea index (OAHI) ≥5 events/hour, confirmed by an in-laboratory polysomnography within the previous 6 months
  • Deemed to require Continuous Positive Airway Pressure (CPAP) therapy as part of usual clinical care
  • Ability of the participant and/or parent or legal guardian to provide (and assent when applicable)

Exclusion criteria

Exclusion Criteria:

  • Predominant or pathological central sleep apnea (central apnea-hypopnea index ≥5 events/hour)
  • Chronic respiratory failure or medical conditions requiring ventilatory support with a set respiratory rate (e.g., neuromuscular disease requiring bilevel ventilation with a backup rate)
  • Hypoventilation requiring non-invasive ventilation with a set respiratory rate
  • History of pneumothorax or pneumomediastinum
  • Uncontrolled gastroesophageal reflux and/or recurrent vomiting
  • Uncontrolled oral secretions
  • Prior use of CPAP or High-Flow Nasal Cannula therapy for treatment of obstructive sleep apnea within the previous 12 months
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
258 participants (estimated)

Study arms

  • Active comparator
    Continuous Positive Airway Pressure (CPAP)

    Participants assigned to this arm will receive Continuous Positive Airway Pressure (CPAP) therapy for the treatment of obstructive sleep apnea. CPAP delivers pressurized air through a mask worn during sleep to keep the airway open. Participants will use CPAP at home each night during sleep for a three-month intervention period, with device settings optimized based on standard clinical care.

    Device: Continuous Positive Airway Pressure

  • Experimental
    High-Flow Nasal Cannula (HFNC)

    Participants assigned to this arm will receive High-Flow Nasal Cannula (HFNC) therapy for the treatment of obstructive sleep apnea. HFNC delivers warmed, humidified air at high flow rates through soft nasal prongs to support airway patency during sleep. Participants will use HFNC at home each night during sleep for a three-month intervention period, with flow settings optimized based on standard clinical care.

    Device: High Flow Nasal Cannula

Interventions

  • DeviceHigh Flow Nasal Cannula

    High-Flow Nasal Cannula (HFNC) therapy delivers warmed, humidified air at high flow rates through soft nasal prongs during sleep to support upper airway patency in children with obstructive sleep apnea. The therapy is used nightly at home, with flow settings optimized according to standard clinical care and overnight sleep study titration.

  • DeviceContinuous Positive Airway Pressure

    Continuous Positive Airway Pressure (CPAP) therapy delivers pressurized air through a nasal or oronasal mask worn during sleep to maintain upper airway patency and treat obstructive sleep apnea. CPAP therapy is used nightly at home, with pressure settings optimized according to standard clinical care and overnight sleep study titration.

06

What researchers measure

Primary outcomes

  1. Adherence

    Adherence is defined as the average number of hours and minutes of CPAP or High-Flow Nasal Cannula use per night, obtained from objective device-generated data over the intervention period.

    Time frame: 3 months

Secondary outcomes

  1. OSA-Related Quality of Life

    Change from baseline to post-intervention follow-up in obstructive sleep apnea (OSA)-related quality of life, measured using the OSA-18 questionnaire. \[Total score ranges from 18 to 126. A higher score indicates greater negative impact of OSA on the child's quality of life\]

    Time frame: Baseline and 3 months

  2. OSA Symptoms

    Change from baseline to post-intervention follow-up in obstructive sleep apnea symptoms, measured using the Pediatric Sleep Questionnaire (PSQ). \[Total score ranges from 0 to 1. A higher score indicates a greater frequency and severity of sleep-disordered breathing symptoms\]

    Time frame: Baseline and 3 months

  3. Sleep Quality and Disturbance

    Change from baseline to post-intervention follow-up in sleep quality and sleep disturbance, measured using the Sleep Disturbance Scale for Children (SDSC). Total score ranges from 26 to 130. A higher scores indicates a higher degree of sleep disturbances.

    Time frame: Baseline and 3 months

  4. Insomnia symptoms

    Change from baseline to post-intervention follow-up in insomniac symptoms, measured using insomnia severity index (ISI). The total score ranges from 0 to 28, with a higher score indicating more severe insomnia symptoms, greater sleep distress, and worse daytime impairment

    Time frame: Baseline and 3 months

  5. Daytime Sleepiness

    Change from baseline to post-intervention follow-up in daytime sleepiness, measured using the Epworth Sleepiness Scale for Children and Adolescents (ESS-CHAD). The total score ranges from 0 to 24, with a higher score indicating more severe daytime sleepiness.

    Time frame: Baseline and 3 months

  6. Health-related quality of life

    Change from baseline in KIDSCREEN-10 index, a self-report health-related quality of life scale. Total score ranges from 10-50, with a higher score indicating better quality of life.

    Time frame: Baseline and 3 months

  7. Psychosocial Functioning

    Change from baseline to post-intervention follow-up in psychosocial functioning, measured using age-appropriate versions of the Strengths and Difficulties Questionnaire (SDQ). \[Total score range from 0 to 40. A higher score indicates a higher level of psychological distress or behavioral problems.\]

    Time frame: Baseline and 3 months

  8. Perceived Comfort

    Perceived comfort of using CPAP or High-Flow Nasal Cannula therapy, measured using comfort questionnaires.

    Time frame: 3 months

  9. Barriers to Therapy Use

    Facilitators and barriers to use of continuous positive airway pressure (CPAP) or High-Flow Nasal Cannula (HFNC) therapy, measured using the Adherence Barriers to CPAP/HFNC Questionnaire. Total score ranges from 31 to 155, with a higher score indicating a larger barriers to adhere to the therapy.

    Time frame: 3 months

  10. Caregiver Stress and Burden

    Change from baseline to post-intervention follow-up in caregiver stress and burden, measured using validated caregiver strain questionnaires. \[Total score range from 11 to 55. A higher score indicates greater caregiver strain, burden, and distress.\]

    Time frame: Baseline and 3 months

  11. Self-efficacy

    Self-Efficacy Measure for Sleep Apnea (SEMSA) is used to assess the willingness and confidence to engage in therapy despite potential obstacles. Total score ranges from 22-88. A higher score indicates higher levels of self-efficacy beliefs regarding their therapy for OSA.

    Time frame: Baseline and 3 months

  12. Self-report chronotype

    The circadian phase preference (chronotype) is assessed by reduced morningness-eveningness questionnaire (rMEQ). Total score ranges from 4 to 26. Higher scores (18-26) indicate a morning type, while lower scores (4-11) indicate an evening type (owl), and 12-17 being intermediate.

    Time frame: Baseline and 3 months

  13. Parent-report chronotype

    The circadian phase preference (chronotype) is assessed by a parent-reported instrument, the Children's ChronoType Questionnaire (CCTQ). Total score ranges from 10 to 48, with higher scores indicate greater eveningness, while lower scores indicate stronger morningness. Categories: * \<=23: Morning type * 24-32: Intermediate type * \>=33: Evening type

    Time frame: Baseline and 3 months

  14. Cost-effectiveness - Quality-Adjusted Life Year (QALY)

    Quality-Adjusted Life Year (QALY) is a standard metric used in health economics to measure the benefit of medical treatments by combining both the quality and quantity of life lived. One QALY equals one year of life in perfect health. It is used to compare cost-effectiveness between HFNC and CPAP. QALY gained will be calculated from changes in patient utility, measured by the Health Utilities Index Mark 3 (HUI3), a comprehensive, multi-attribute system used to measure generic health status and health-related quality of life. It calculates a numerical health utility score-typically between 0.00 (dead) and 1.00 (perfect health).

    Time frame: Baseline and 3 months

  15. Cost-effectiveness - Cost Utility

    Cost utility of HFNC compared with CPAP, assessed by the incremental cost-effectiveness ratio (ICER), derived by dividing the incremental costs between HFNC and CPAP by the incremental quality-adjusted life years (QALY) gains.

    Time frame: 3 months

Other outcomes

  1. Participant and Caregiver Experience With Therapy

    Experiences with CPAP and High-Flow Nasal Cannula therapy, including comfort, perceived benefits and challenges, adherence strategies, and caregiver impact, assessed through semi-structured qualitative interviews.

    Time frame: at end of intervention of 3 month

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — Individual participant data (IPD) that are de-identified will be shared upon reasonable request and subject to approval by the study investigators, applicable institutional policies, and data-sharing agreements. IPD sharing may be limited or delayed to protect participant privacy, respect consent provisions, and allow for completion of planned primary and secondary analyses. Data will only be shared for scientifically sound research proposals and in accordance with ethical, legal, and regulatory requirements.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Nov 2031, 66 months after the start.

Of 511 non-industry interventional studies with no phase under Sleep Apnea, Obstructive, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 53. This study's planned 66 months is above that.

Counting every sponsor, half of 629 studies reached it within 27 months; a quarter within 12 and three quarters within 50.

Start moved once since we started tracking on Sep 25, 2026: Jun 2026 → May 2026, on Nov 19, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 7, 2026
First posted
May 20, 2026
StartActual
May 27, 2026was Jun 2026
Primary completionEst.
Nov 2031
CompletionEst.
Dec 2031
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 19, 2026
Sites
The Hospital for Sick Children is now Recruiting
Nov 19, 2026
Start date
Jun 1, 2026→May 27, 2026 (actual)
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Not yet recruiting→Recruiting
    The Hospital for Sick Children is now Recruiting
    Start date Jun 1, 2026→May 27, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07600333
Responsible party
Indra Narang (VP, Health Equity and Inclusion, The Hospital for Sick Children) — Principal investigator
First posted
May 20, 2026
Start date
May 27, 2026
Primary completion
Nov 2031 (estimated)
Completion
Dec 2031 (estimated)
Last update
Nov 19, 2026

Study contacts

Aditi Garg
Contact
aditi.garg@sickkids.ca
(416) 813 6809
Indra Narang
principal investigator · The Hospital for Sick Children

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion